Ordin nr. 1301/500/2008 din 11 iulie 2008 Partea a ii-a

terapii imunosupresoare, la pacienţii adulţi.

Profilaxia rejetului de grefă la pacienţii care primesc

transplant hepatic alogen.

Se aplică tuturor denumirilor comerciale, formelor farmaceutice şi concentraţiilor corespunzătoare DCI-ului.
________________________________________________________________________________

DCI/DENUMIRE COMERCIALĂ FORMA FARM.

__________________________________________________

CONCENTRAŢIE FIRMA

________________________________________________________________________________

L04AA05 TACROLIMUSUM CAPS. ELIB. PREL 0,5 mg

ADVAGRAF 0,5 mg 0,5 mg ASTELLAS PHARMA GMBH
L04AA05 TACROLIMUSUM CAPS. 0.5 mg

PROGRAF(R) 0,5 mg 0.5 mg ASTELLAS PHARMA GMBH

L04AA05 TACROLIMUSUM CAPS. 1 mg

PROGRAF(R) 1 mg 1 mg ASTELLAS IRELAND CO. LTD.

L04AA05 TACROLIMUSUM CAPS. ELIB. PREL. 1 mg

ADVAGRAF 1 mg 1 mg ASTELLAS PHARMA GMBH

L04AA05 TACROLIMUSUM CAPS. 5 mg

PROGRAF(R) 5 mg 5 mg ASTELLAS PHARMA GMBH

L04AA05 TACROLIMUSUM CAPS. ELIB. PREL. 5 mg

ADVAGRAF 5 mg 5 mg ASTELLAS PHARMA GMBH

L04AA05 TACROLIMUSUM CONC. PT. SOL. PERF. 5 mg/ml

PROGRAF(R) 5 mg/ml 5 mg/ml ASTELLAS PHARMA GMBH

________________________________________________________________________________
______________________________________________________________________________

| 956 |L04AA06| MYCOPHENOLATUM** | |

|_______|_______|____________________________________________|_________________|
Prescriere limitată: Profilaxia rejetului acut de grefă la pacienţii care primesc transplant alogen hepatic.
________________________________________________________________________________

DCI/DENUMIRE COMERCIALĂ FORMA FARM.

__________________________________________________

CONCENTRAŢIE FIRMA

________________________________________________________________________________

L04AA06 MYCOPHENOLATUM COMPR. FILM. GASTROREZ. 180 mg

MYFORTIC 180 mg 180 mg NOVARTIS PHARMA GMBH
L04AA06 MYCOPHENOLATUM PULB. PT. SUSP. ORALA 1 g/5 ml

CELLCEPT 1 mg/5 ml 1 g/5 ml ROCHE REGISTRATION LTD.

Prescriere limitată: Profilaxia rejetului acut de grefă la pacienţii care primesc transplant alogen hepatic
L04AA06 MYCOPHENOLATUM CAPS. 250 mg

CELLCEPT 250 mg 250 mg ROCHE REGISTRATION LTD.

MYFENAX 250 mg 250 mg TEVA PHARMA BV
Prescriere limitată: Profilaxia rejetului acut de grefă la pacienţii care primesc transplant alogen hepatic
L04AA06 MYCOPHENOLATUM COMPR. FILM. GASTROREZ. 360 mg

MYFORTIC 360 mg 360 mg NOVARTIS PHARMA GMBH

L04AA06 MYCOPHENOLATUM CAPS. 500 mg

MYFENAX 500 mg 500 mg TEVA PHARMA BV

Prescriere limitată: Profilaxia rejetului acut de grefă la pacienţii care primesc transplant alogen hepatic
L04AA06 MYCOPHENOLATUM COMPR. FILM. 500 mg

CELLCEPT 500 mg 500 mg ROCHE REGISTRATION LTD.

L04AA06 MYCOPHENOLATUM PULB. PT. CONC. PT. 500 mg

SOL. PERF.

CELLCEPT 500 mg 500 mg ROCHE REGISTRATION LTD.

________________________________________________________________________________

______________________________________________________________________________

| 957 |L04AA10| SIROLIMUS** | |

|_______|_______|____________________________________________|_________________|
________________________________________________________________________________

DCI/DENUMIRE COMERCIALĂ FORMA FARM.

__________________________________________________

CONCENTRAŢIE FIRMA

________________________________________________________________________________

L04AA10 SIROLIMUS COMPR. FILM. 1 mg

RAPAMUNE 1 mg 1 mg WYETH EUROPA LTD.
Monitorizarea atentă a pacienţilor este obligatorie
________________________________________________________________________________
SUBLISTA C2 - P9: PROGRAM NAŢIONAL DE TRANSPLANT DE ORGANE, ŢESUTURI ŞI CELULE DE ORIGINE UMANĂ. P9.4 TRANSPLANT RENAL, TRANSPLANT COMBINAT RINICHI ŞI PANCREAS
______________________________________________________________________________

| 958 |A05AA02| ACIDUM URSODEOXYCHOLICUM | |

|_______|_______|____________________________________________|_________________|
NOTĂ: